‘First drug of its kind’ flu medication gains approval

drugs to treat the flu now include xofluza a new antiviral the fda just approved
Image credit: Bustle

The flu vaccine remains the best proactive way to protect yourself and your loved ones from the influenza virus. But this upcoming flu season, there’ll be a new weapon available against the nasty disease. On [October 25], the Food and Drug Administration announced their approval of a new antiviral treatment for the flu, said to be the first drug of its kind. The drug is formally known as baloxavir marboxil, but will be sold under the trade name Xofluza.

What makes Xofluza particularly exciting is that it goes after the virus in a different way than the only other class of flu antivirals currently do. It inhibits something called the cap-dependent endonuclease protein, which the virus needs to make more copies of itself. That, ideally, should mean that it can treat flu infections resistant to older drugs.

Related article:  Podcast: Don't treat that fever—Dr. Paul Offit on why many of medicine's most popular practices are 'overkill'


The two clinical trials evaluated by the FDA for approval—which involved nearly 2,000 patients—showed that Xofluza was able to shorten the duration and reduce the severity of flu symptoms when compared to a placebo.

The results of these trials, according to Shiogi researchers, also suggested that Xofluza could be even more effective at treating high-risk groups like the elderly than typical treatments; it might also stop the virus from replicating sooner, which would reduce the chances of further transmission.

Read full, original post: We Now Have a New Drug to Treat the Flu

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend